A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine ...
The Trump administration's freeze on Health and Human Services data is causing concern among officials in the Lane County ...
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
1don MSN
The Miami Heat and the Golden State Warriors have agreed on a deal that sends Jimmy Butler to the Bay Area, a person with ...
NFL Commissioner Roger Goodell shot down the perception that officials favor the Kansas City Chiefs, saying it’s a ...
The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively.
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback